Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
1. Cytokinetics presented data showing aficamten's superiority over metoprolol. 2. Annual AF incidence with aficamten is 1.5%, aligning with predictions. 3. Long-term use of aficamten shows sustained benefits and safety. 4. Cytokinetics will host an investor webcast on Sep 2, 2025.